Disc Medicine, INC

Disc Medicine reported Q2 2026 financial results, highlighting strong cash position and progress across its hematologic disease pipeline, with key data readouts expected in late 2026.

Disc Medicine has amended its loan agreement with Hercules Capital, extending drawdown periods for future advances and modifying cash covenant terms.

Disc Medicine, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of directors and ratification of its accounting firm.

Disc Medicine announced its first quarter 2026 financial results, highlighting progress in its clinical pipeline and a strong cash position.

Disc Medicine, Inc. announced a 20% workforce reduction and a $2.0 million restructuring charge following an FDA Complete Response Letter for its drug bitopertin.

Disc Medicine announced its Q4 and full-year 2025 financial results, highlighted by pipeline progress and a strong cash position, despite a Complete Response Letter for bitopertin.

Disc Medicine, Inc. reported its financial results for the second quarter of 2026, highlighting progress in its hematologic disease pipeline and providing an update on its bitopertin program.

Disc Medicine Inc. reported its Q1 2026 financial results, highlighting increased R&D expenses and providing an update on the bitopertin New Drug Application (NDA) status.

Disc Medicine reports increased losses but a strong cash position into 2029, driven by a recent $210.9 million capital raise and accelerated FDA review for bitopertin in EPP and XLP.

Disc Medicine, a clinical-stage biopharmaceutical company, reported increased R&D expenses and net losses in Q2 2025, but maintains a strong cash position to fund operations into 2028, driven by progress in its hematologic disease pipeline and a planned October 2025 NDA submission for bitopertin.

Disc Medicine reports a net loss of $34.1 million for Q1 2025 while advancing its clinical programs and maintaining a strong cash position.

Disc Medicine, a clinical-stage biopharmaceutical company, released its third-quarter 2024 results, highlighting progress in its hematologic disease programs and financial position.

Disc Medicine received a Complete Response Letter from the FDA for bitopertin's accelerated approval in EPP and XLP, while reporting increased net losses and a strong cash position.

Disc Medicine's 10-K filing highlights the company's focus on hematologic diseases, plans for bitopertin's accelerated approval, and ongoing clinical trials for other product candidates.

Disc Medicine, a clinical-stage biopharmaceutical company, released its 2023 financial results and provided an update on its clinical pipeline, highlighting progress in its hematologic disease programs.

John D Quisel, Chief Executive Officer and a Director of Disc Medicine, Inc., sold 33,000 shares of common stock on July 13, 2026.

Disc Medicine COO Jonathan Yu executed trades involving company stock and stock options under a pre-arranged 10b5-1 plan.

Disc Medicine's Chief Legal Officer, Rahul Khara, executed trades involving company stock and stock options under a pre-arranged 10b5-1 plan.

Disc Medicine, Inc. (IRON) reports that Chief Operating Officer Jonathan Yen-Wen Yu executed a Rule 10b5-1 trading plan, involving the acquisition and disposition of company stock.

Disc Medicine COO Jonathan Yen-Wen Yu reports sale of 9,700 common shares and acquisition of 9,700 shares via stock option exercise under a pre-arranged trading plan.

Disc Medicine, Inc. Chief Operating Officer Jonathan Yen-Wen Yu executed a Rule 10b5-1 trading plan, resulting in the sale of company stock and the acquisition of stock options.

Disc Medicine, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory votes.

Disc Medicine, Inc. has filed a definitive proxy statement with the SEC.

Disc Medicine announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, featuring director elections, executive compensation votes, and auditor ratification.

Disc Medicine will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Disc Medicine, Inc. will hold its annual stockholder meeting virtually on June 9, 2023, to vote on the election of directors and the ratification of the company's independent registered public accounting firm.

Atlas Venture funds have reduced their beneficial ownership in Disc Medicine, Inc. to below 5% primarily due to dilution from new share issuances, alongside recent stock sales.

AI DMI LLC, an entity controlled by Len Blavatnik, completed a secondary offering of Disc Medicine, Inc. common stock, generating $58.7 million in net proceeds.

Atlas Venture entities have significantly reduced their beneficial ownership in Disc Medicine, Inc. through a series of common stock sales.

OrbiMed Advisors and its affiliated entities have filed an Amendment No. 5 to their Schedule 13D, indicating they have ceased to be beneficial owners of more than 5% of Disc Medicine, Inc.'s common stock following recent share dispositions.

Access Industries and its affiliated entities have filed an Amendment No. 5 to their Schedule 13D, confirming their continued beneficial ownership of 10.8% of Disc Medicine, Inc.'s common stock.

RA Capital Management and its affiliates have reported a 5.9% passive ownership stake in Disc Medicine, Inc., totaling 2,228,924 shares.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 14.1% in Disc Medicine Inc., totaling 4,907,158.99 common shares.

Frazier Life Sciences and its affiliates filed an amended Schedule 13G, clarifying their beneficial ownership in DISC Medicine, Inc. and correcting prior attribution.

Wellington Management Group and its affiliates reported a 4.1% beneficial ownership stake in Disc Medicine, Inc. as of June 30, 2025, holding 1,432,090 common shares.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 12.2% in Disc Medicine Inc.'s common stock as of July 31, 2025.

Paradigm BioCapital Advisors LP, its general partner, and its managing member, along with Paradigm BioCapital International Fund Ltd., have filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.5% in Disc Medicine, Inc.'s common stock as of March 31, 2025.